Bionexus Gene Lab CORP 8-K filings

BioNexus Gene Lab Corp. announces progress in commercializing its VitaGuard MRD platform in Southeast Asia following a working visit to China, with initial deployments targeted for 2026.

BioNexus Gene Lab Corp. highlighted its strategic vision for cross-border biotechnology co-development at the 2026 China-Malaysia Economic Cooperation Outlook Forum.

BioNexus Gene Lab Corp. announced the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to lead global commercialization efforts for its VitaGuard MRD platform.

BioNexus Gene Lab Corp. announced a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., streamlining its board and appointing Matthew L. Barsing as Chairman.

BioNexus Gene Lab Corp. announced the formal commencement of its 2026 regional deployment phase for the VitaGuard Minimal Residual Disease (MRD) platform in Southeast Asia.

BioNexus Gene Lab Corp. stockholders approved the election of directors, a 2025 Equity Incentive Plan, and the independent auditor at their Annual Meeting.

BioNexus Gene Lab Corp. announced the resignations of four officers and directors from its Chemrex subsidiary amidst an ongoing governance review and strategic shift towards biotechnology.

BioNexus Gene Lab Corp. announced a $500 million equity purchase agreement with ARC Group International and an exclusive license for the VitaGuard MRD platform in Southeast Asia.

BioNexus Gene Lab Corp. announced the filing of a $100 million shelf registration and the establishment of a $20 million at-the-market equity program to fund strategic growth initiatives.

BioNexus Gene Lab Corp. has entered into definitive agreements with Fidelion Diagnostics to commercialize the VitaGuard minimal-residual-disease platform in Southeast Asia through a cross-equity strategic alliance.

BioNexus Gene Lab Corp has signed a non-binding term sheet with BirchBioMed Inc. for a strategic partnership involving equity investment and commercialization of the FS2 topical platform in Southeast Asia.

BioNexus Gene Lab Corp. announced a non-binding term sheet with Fidelion Diagnostics Pte Ltd for a cross-equity strategic alliance and exclusive commercialization rights for Fidelion's VitaGuard minimal-residual-disease platform in Southeast Asia.

BioNexus Gene Lab Corp. has appointed Ms. Chong Set Fui (Angeline), a seasoned financial leader with over 25 years of experience, as its new Chief Financial Officer and Principal Financial Officer, effective immediately.

BioNexus Gene Lab Corp. announces it has regained compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share.

BioNexus Gene Lab Corp. enacted a 1-for-10 reverse stock split on April 7, 2025, to meet Nasdaq's minimum bid price requirement.

BioNexus Gene Lab Corp. will implement a 1-for-10 reverse stock split, effective April 7, 2025, to address its bid price deficiency and maintain its NASDAQ listing.

BioNexus Gene Lab Corp. shareholders voted to approve a reverse stock split and the adjournment of a special meeting if needed to solicit additional proxies.

BioNexus Gene Lab Corp. announces a strategic partnership with ML Tech to optimize its Ethereum-based growth strategies.

BioNexus Gene Lab Corp. (BGLC) announces its Board's approval of a new treasury strategy focused exclusively on Ethereum (ETH), positioning the company as a leader among Nasdaq-listed firms in prioritizing Ethereum for treasury management.

BioNexus Gene Lab Corp. has created a new Series Z Preferred Stock to increase the likelihood of a successful reverse stock split vote.

BioNexus Gene Lab Corp. has received an extension until May 1, 2025, to meet Nasdaq's minimum bid price requirement and plans a reverse stock split by April 7, 2025, if necessary.

BioNexus Gene Lab Corp. received a delisting notice from Nasdaq due to its failure to maintain a minimum share price, while also appointing a new independent director and a new president.

BioNexus Gene Lab Corp. reports the immediate resignation of two board members, Wei Foong Lim and Koon Wai Wong, effective October 9, 2024.

BioNexus Gene Lab Corp.'s 2024 Annual Meeting saw the re-election of directors and auditor, but key proposals for a stock incentive plan and reverse stock split were rejected amidst allegations of a dissident proxy solicitation.

BioNexus Gene Lab Corp. subsidiary, MRNA Scientific, has partnered with Protech Builders to develop and operate biogas plants in Malaysia, focusing on converting plantation wastewater into renewable energy.

BioNexus Gene Lab Corp.'s subsidiary, MRNA Scientific, has partnered with VITARRAY Global to provide mRNA dynamic gene detection services in Southeast Asia, aiming to improve early disease detection.

BioNexus Gene Lab Corp is expanding its operations through a new color paste production line and a strategic partnership focused on cancer screening and preventative healthcare.

BioNexus Gene Lab Corp. has amended its bylaws to reduce the quorum requirement for shareholder meetings from a majority to one-third of outstanding shares.

BioNexus Gene Lab Corp. reports a successful co-investment by the Malaysian Securities Commission into Ascension Innovation Sdn Bhd, highlighting confidence in its innovative healthcare technology.

BioNexus Gene Lab Corp. has finalized a RM 1 million investment in Ascension Innovation Sdn Bhd to enhance its digital health presence and genomic screening services.